BioSpace News Archive

Cambrian Biopharma today announced a licensing agreement with Novartis to advance novel, selective compounds designed and characterized by Novartis to target the mechanistic target of rapamycin (mTOR) pathway.

Bristol Myers Squibb (NYSE: BMY) today announced that VALOR-HCM, the Phase 3 randomized, double-blind, placebo-controlled study evaluating mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM) who are eligible for septal reduction therapy (SRT), met its primary endpoint at Week 16.

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2021 and provided financial expectations for 2022.

Marinus Pharmaceuticals, Inc. today announced plans to provide a business update and preliminary financial results for the fourth quarter and fiscal year ended December 31, 2021 before the market opens on March 21, 2022.

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2021 and reaffirmed guidance for 2022.

Company’s first-in-class approach to targeting of signal regulatory proteins (SIRP) enables specific depletion of pathological immune cells.

Acquisition includes two first-in-class clinical-stage assets and proprietary product discovery platform.

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that it has repaid its debt of $39.1 million to Structured Alpha LP (“SALP”) in full, using cash on hand.

Mydecine Innovations Group Inc. today announced the inclusion of a novel molecule with potentially heart-safe microdose enabling properties in their family of psilocin analogs.

Otonomy, Inc. today announced two upcoming presentations on the OTO-413 hearing loss program at the 49th Annual Scientific and Technology Meeting of the American Auditory Society (AAS) to be held February 24-26, 2022 in Scottsdale, Arizona.